In-stent Restenosis
3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
AbbottABBOTT PARK, IL
2 programs1
Coronary angioplasty using the paclitaxel-eluting balloonPhase 41 trial
Drug Eluting BalloonN/A1 trial
Active Trials
Reflow MedicalCA - San Clemente
1 program1
Drug-eluting Coronary Spur Stent SystemPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbottCoronary angioplasty using the paclitaxel-eluting balloon
CordisSirolimus-Eluting Bx Velocity® Balloon Expandable Stent
Reflow MedicalDrug-eluting Coronary Spur Stent System
AbbottDrug Eluting Balloon
Clinical Trials (4)
Total enrollment: 755 patients across 4 trials
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)
Start: Jan 2010310 patients
Phase 4Unknown
Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)
Start: Feb 2003Est. completion: Sep 2009384 patients
Phase 3Completed
Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)
Start: Jun 2024Est. completion: Jul 202610 patients
Phase 1Active Not Recruiting
CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
Start: Oct 2021Est. completion: May 202551 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space